Developer docs
API playgroundTry for free, no card

Search company profiles

Istesso

Full company profile

uuid0002kcq

Namestring
Istesso
Legal namestring
Istesso Limited
Websiteurl
istesso.co.uk
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Istesso Limited is a London-based clinical-stage biopharmaceutical company founded in 2017 that develops first-in-class oral regenerative medicines based on Mitochondrial Complex I Modulators (MCMs), a proprietary class of small-molecule drugs designed to activate the body's natural tissue repair mechanisms rather than suppress disease symptoms. The company's lead clinical asset, leramistat (IST-03, formerly MBS2320), is an oral small molecule in Phase 2 development for secondary sarcopenia in rheumatoid arthritis patients, with clinical sites at Newcastle University and Newcastle Hospitals in conjunction with the National Institute for Health and Care Research (NIHR). The pipeline additionally includes development candidate MBS2687 — an orally available MCM with best-in-class potential — and discovery-stage asset IST003.

Leramistat has previously received FDA Fast Track designation and Orphan Drug Designation for idiopathic pulmonary fibrosis, and the company has published peer-reviewed preclinical data in The Journal of Pharmacology and Experimental Therapeutics demonstrating muscle quality restoration in aged mouse models and tissue-protective effects in collagen-induced arthritis models. As of June 2026, the IST-03 Phase 2 sarcopenia trial represents a strategic refocus of the lead asset toward musculoskeletal repair following Phase 2b rheumatoid arthritis results showing muscle-protective effects.

The company is pre-revenue and does not currently commercialize any products; its expected future revenue model centers on pharmaceutical product sales following regulatory approval, supplemented by licensing and co-development agreements with larger partners — exemplified by an Option and Licence Agreement with Janssen Biotech Inc. for MBS2320. Istesso is controlled by FTSE-listed IP Group plc, which holds an undiluted 56.5% stake; approximately £10 million has been disclosed as raised across 2018-2019 financing rounds from IP Group, Parkwalk Advisors, and Puhua Capital. Leadership includes CEO and co-founder Lisa Patel (former GSK), Executive Chairman Sam Williams (Managing Partner, IP Group Life Sciences), and non-executive directors Peter Allen (former CFO of Celltech), Professor Sir Keith Peters (former Regius Professor of Physic at Cambridge) and Dr Michael Owen (former SVP at GSK and Kymab co-founder).

Short descriptiontext

Istesso is a London-based clinical-stage biopharmaceutical company developing first-in-class oral Mitochondrial Complex I Modulators (MCMs) for tissue repair, with lead asset leramistat in Phase 2 trials for sarcopenia in rheumatoid arthritis patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicines, drug discovery, clinical-stage biopharmaceuticals, mitochondrial complex modulators, small molecule therapeutics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Clinical-stage Biopharmaceuticals / Regenerative Medicine
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Istesso is a clinical-stage biopharmaceutical company developing novel regenerative medicines. The company is pre-revenue and does not currently commercialize any products. Future revenue is expected to come from pharmaceutical product sales following regulatory approval, potential licensing agreements, and co-development partnerships with larger pharmaceutical companies.

istesso.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Istesso is a clinical-stage biopharmaceutical company developing first-in-class oral regenerative medicines based on mitochondrial Complex I modulators (MCMs), a novel class of small molecule drugs that activate the body's natural repair mechanisms to regenerate damaged tissue. Its lead clinical candidate, leramistat, is in Phase 2 trials for sarcopenia caused by rheumatoid arthritis, with a broader pipeline targeting chronic age-related diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 2 trial IST-03 initiated June 2026 for sarcopenia in rheumatoid arthritis patients at Newcastle University and Newcastle Hospitals
+4 more records
Product overview1 text field

Istesso is developing pioneering oral regenerative medicines focused on mitochondrial Complex I modulators (MCMs). The company's lead clinical program is leramistat (formerly MBS2320), a first-in-class oral small molecule drug in Phase 2 trials for musculoskeletal repair in secondary sarcopenia. The pipeline includes MBS2687 (development candidate) and IST003 as additional assets, each targeting chronic age-related diseases with blockbuster potential. The MCM platform enables tissue repair and regeneration across multiple organs by activating the body's own repair mechanisms without immunosuppression.

Product and service4 records
1Leramistat
CategoryCore clinical product
Description

First-in-class oral regenerative medicine and mitochondrial Complex I modulator (MCM) in Phase 2 development for musculoskeletal repair in secondary sarcopenia. Restores damaged tissue and builds resilience without suppressing the immune system.

2MBS2687
CategoryPipeline development candidate
Description

Orally available small-molecule MCM with best-in-class potential. Development candidate nominated for primary adaptive repair in indications to be determined.

3IST003
CategoryPipeline asset
Description

Pipeline asset in discovery/preclinical stage as part of Istesso's MCM programme targeting chronic age-related conditions.

4MBS2320
CategoryFormer product name (predecessor to leramistat)
Description

Former designation/name for leramistat. First-in-class metabolic reprogramming agent with dual mode-of-action reducing inflammation and supporting tissue remodelling. Previously in clinical development for rheumatoid arthritis and IPF.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Phase 2 clinical trial IST-03 being conducted at Newcastle University and Newcastle Hospitals, working with the National Institute for Health and Care Research (NIHR). Dr Josh Bennett serves as Investigator at Newcastle University. Trial sites feature specialist facilities and biopsy expertise including advanced imaging and analysis techniques.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-12-01
Description

Istesso has an Option and Licence Agreement with Janssen Biotech Inc. for MBS2320, a first-in-class metabolic reprogramming agent for the treatment of rheumatoid arthritis with dual mode-of-action.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing mitochondria-targeted therapies (e.g., elamipretide) addressing mitochondrial dysfunction across multiple indications; comparable to Istesso's Mitochondrial Complex I Modulator approach to harnessing mitochondrial biology for disease modification.

TypeEmerging player
Description

Clinical-stage biotech using AI and human aging biology to develop therapeutics for metabolic and muscle-related diseases of aging; comparable due to overlapping sarcopenia/metabolic disease focus and emphasis on novel oral small molecules.

TypeEmerging player
Description

Clinical-stage company developing therapeutics that target cellular senescence and aim to restore tissue function in age-related diseases; comparable to Istesso through a shared 'repair rather than suppress' thesis targeting chronic age-related conditions.

4CohBar (now shareholders-led)
TypeEmerging player
Description

Previously developed mitochondria-derived peptides (MDPs) for age-related diseases including NASH and obesity-related indications; a thematic peer in mitochondrial-based therapeutics for chronic age-related conditions, though small-molecule delivery differs from Istesso's MCM approach.

TypeOthers
Description

Pre-clinical biotech developing small-molecule therapeutics that improve mitochondrial function in Duchenne muscular dystrophy and other indications; acquired by Astellas in 2018, illustrating the established pharma appetite for mitochondrial-targeted assets comparable to Istesso's MCM platform.

6AgeX Therapeutics
TypeEmerging player
Description

Company focused on regenerative medicine and tissue repair technologies targeting age-related degenerative conditions; comparable to Istesso through a shared regenerative-medicine thesis, though operating at the cellular/pluripotent stem cell level rather than small molecules.

TypeEmerging player
Description

Clinical-stage biotech developing mitochondrial-targeted therapies and gene therapies for neurodegenerative diseases of the eye; shares Istesso's mitochondrial therapeutic focus, though delivery modality differs.

TypeDirect peer
Description

Netherlands-based clinical-stage biotech developing mitochondrial-targeted small molecules to treat mitochondrial diseases; shares Istesso's strategy of modulating mitochondrial bioenergetics with orally bioavailable drugs.

TypeDirect peer
Description

Swedish clinical-stage biotech developing small-molecule modulators of mitochondrial Complex I and related pathways for primary mitochondrial diseases and broader indications; the closest direct mechanistic peer to Istesso's MCM platform.

TypeBroad incumbent
Description

Acquired by Biogen in 2023, Reata developed bardoxolone methyl (Nrf2 activator with mitochondrial effects) approved for Friedreich's ataxia; comparable as an established mitochondrial-mechanism drug developer that validated the space commercially via a major-pharma acquisition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Istesso

Clinical-stage Biopharmaceuticals / Regenerative Medicineistesso.co.uk

Istesso is a London-based clinical-stage biopharmaceutical company developing first-in-class oral Mitochondrial Complex I Modulators (MCMs) for tissue repair, with lead asset leramistat in Phase 2 trials for sarcopenia in rheumatoid arthritis patients.

What Istesso does

Istesso Limited is a London-based clinical-stage biopharmaceutical company founded in 2017 that develops first-in-class oral regenerative medicines based on Mitochondrial Complex I Modulators (MCMs), a proprietary class of small-molecule drugs designed to activate the body's natural tissue repair mechanisms rather than suppress disease symptoms. The company's lead clinical asset, leramistat (IST-03, formerly MBS2320), is an oral small molecule in Phase 2 development for secondary sarcopenia in rheumatoid arthritis patients, with clinical sites at Newcastle University and Newcastle Hospitals in conjunction with the National Institute for Health and Care Research (NIHR). The pipeline additionally includes development candidate MBS2687 — an orally available MCM with best-in-class potential — and discovery-stage asset IST003.

Leramistat has previously received FDA Fast Track designation and Orphan Drug Designation for idiopathic pulmonary fibrosis, and the company has published peer-reviewed preclinical data in The Journal of Pharmacology and Experimental Therapeutics demonstrating muscle quality restoration in aged mouse models and tissue-protective effects in collagen-induced arthritis models. As of June 2026, the IST-03 Phase 2 sarcopenia trial represents a strategic refocus of the lead asset toward musculoskeletal repair following Phase 2b rheumatoid arthritis results showing muscle-protective effects.

The company is pre-revenue and does not currently commercialize any products; its expected future revenue model centers on pharmaceutical product sales following regulatory approval, supplemented by licensing and co-development agreements with larger partners — exemplified by an Option and Licence Agreement with Janssen Biotech Inc. for MBS2320. Istesso is controlled by FTSE-listed IP Group plc, which holds an undiluted 56.5% stake; approximately £10 million has been disclosed as raised across 2018-2019 financing rounds from IP Group, Parkwalk Advisors, and Puhua Capital. Leadership includes CEO and co-founder Lisa Patel (former GSK), Executive Chairman Sam Williams (Managing Partner, IP Group Life Sciences), and non-executive directors Peter Allen (former CFO of Celltech), Professor Sir Keith Peters (former Regius Professor of Physic at Cambridge) and Dr Michael Owen (former SVP at GSK and Kymab co-founder).

Istesso firmographics

Firmographics
Name
Istesso
Legal name
Istesso Limited
Website
https://istesso.co.uk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Istesso is a London-based clinical-stage biopharmaceutical company developing first-in-class oral Mitochondrial Complex I Modulators (MCMs) for tissue repair, with lead asset leramistat in Phase 2 trials for sarcopenia in rheumatoid arthritis patients.
Ownership category
akta.pro rank

Where Istesso is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Istesso business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development: Istesso is a clinical-stage biopharmaceutical company developing novel regenerative medicines. The company is pre-revenue and does not currently commercialize any products. Future revenue is expected to come from pharmaceutical product sales following regulatory approval, potential licensing agreements, and co-development partnerships with larger pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Istesso product offering

Product offering

Core offering

Istesso is a clinical-stage biopharmaceutical company developing first-in-class oral regenerative medicines based on mitochondrial Complex I modulators (MCMs), a novel class of small molecule drugs that activate the body's natural repair mechanisms to regenerate damaged tissue. Its lead clinical candidate, leramistat, is in Phase 2 trials for sarcopenia caused by rheumatoid arthritis, with a broader pipeline targeting chronic age-related diseases.

Product overview

Istesso is developing pioneering oral regenerative medicines focused on mitochondrial Complex I modulators (MCMs). The company's lead clinical program is leramistat (formerly MBS2320), a first-in-class oral small molecule drug in Phase 2 trials for musculoskeletal repair in secondary sarcopenia. The pipeline includes MBS2687 (development candidate) and IST003 as additional assets, each targeting chronic age-related diseases with blockbuster potential. The MCM platform enables tissue repair and regeneration across multiple organs by activating the body's own repair mechanisms without immunosuppression.

Differentiator

Problem solved

Functional benefit

Products and services

  • Leramistat First-in-class oral regenerative medicine and mitochondrial Complex I modulator (MCM) in Phase 2 development for musculoskeletal repair in secondary sarcopenia. Restores damaged tissue and builds resilience without suppressing the immune system.
  • MBS2687 Orally available small-molecule MCM with best-in-class potential. Development candidate nominated for primary adaptive repair in indications to be determined.
  • IST003 Pipeline asset in discovery/preclinical stage as part of Istesso's MCM programme targeting chronic age-related conditions.
  • MBS2320 Former designation/name for leramistat. First-in-class metabolic reprogramming agent with dual mode-of-action reducing inflammation and supporting tissue remodelling. Previously in clinical development for rheumatoid arthritis and IPF.

Quantifiable outcome

  • Phase 2 trial IST-03 initiated June 2026 for sarcopenia in rheumatoid arthritis patients at Newcastle University and Newcastle Hospitals
  • +4 more outcomes

Companies that use Istesso

Customer profile

Segments3 records

Ideal customer profiles2 records

Istesso technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Istesso partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Newcastle University and Newcastle HospitalscoreStrategic or Co-development Partner · 16 June 2026Phase 2 clinical trial IST-03 being conducted at Newcastle University and Newcastle Hospitals, working with the National Institute for Health and Care Research (NIHR). Dr Josh Bennett serves as Investigator at Newcastle University. Trial sites feature specialist facilities and biopsy expertise including advanced imaging and analysis techniques.
  • Janssen Biotech Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 December 2022Istesso has an Option and Licence Agreement with Janssen Biotech Inc. for MBS2320, a first-in-class metabolic reprogramming agent for the treatment of rheumatoid arthritis with dual mode-of-action.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Istesso competitors and assessment

Company assessment

Direct peers

  • Stealth BioTherapeutics: Clinical-stage biopharmaceutical company developing mitochondria-targeted therapies (e.g., elamipretide) addressing mitochondrial dysfunction across multiple indications; comparable to Istesso's Mitochondrial Complex I Modulator approach to harnessing mitochondrial biology for disease modification.
  • Khondrion: Netherlands-based clinical-stage biotech developing mitochondrial-targeted small molecules to treat mitochondrial diseases; shares Istesso's strategy of modulating mitochondrial bioenergetics with orally bioavailable drugs.
  • Abliva (formerly NeuroVive Pharmaceutical): Swedish clinical-stage biotech developing small-molecule modulators of mitochondrial Complex I and related pathways for primary mitochondrial diseases and broader indications; the closest direct mechanistic peer to Istesso's MCM platform.

Emerging players

  • BioAge Labs: Clinical-stage biotech using AI and human aging biology to develop therapeutics for metabolic and muscle-related diseases of aging; comparable due to overlapping sarcopenia/metabolic disease focus and emphasis on novel oral small molecules.
  • UNITY Biotechnology: Clinical-stage company developing therapeutics that target cellular senescence and aim to restore tissue function in age-related diseases; comparable to Istesso through a shared 'repair rather than suppress' thesis targeting chronic age-related conditions.
  • CohBar (now shareholders-led): Previously developed mitochondria-derived peptides (MDPs) for age-related diseases including NASH and obesity-related indications; a thematic peer in mitochondrial-based therapeutics for chronic age-related conditions, though small-molecule delivery differs from Istesso's MCM approach.
  • AgeX Therapeutics: Company focused on regenerative medicine and tissue repair technologies targeting age-related degenerative conditions; comparable to Istesso through a shared regenerative-medicine thesis, though operating at the cellular/pluripotent stem cell level rather than small molecules.
  • GenSight Biologics: Clinical-stage biotech developing mitochondrial-targeted therapies and gene therapies for neurodegenerative diseases of the eye; shares Istesso's mitochondrial therapeutic focus, though delivery modality differs.

Others

  • Mitobridge (acquired by Astellas): Pre-clinical biotech developing small-molecule therapeutics that improve mitochondrial function in Duchenne muscular dystrophy and other indications; acquired by Astellas in 2018, illustrating the established pharma appetite for mitochondrial-targeted assets comparable to Istesso's MCM platform.

Broad incumbents

  • Reata Pharmaceuticals: Acquired by Biogen in 2023, Reata developed bardoxolone methyl (Nrf2 activator with mitochondrial effects) approved for Friedreich's ataxia; comparable as an established mitochondrial-mechanism drug developer that validated the space commercially via a major-pharma acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Istesso social profiles

Digital presence

Istesso financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Istesso leadership team

Management profile

Number of profiles

Profiles1 record

Istesso funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Istesso M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Istesso

What does Istesso do?

Istesso is a clinical-stage biopharmaceutical company developing first-in-class oral regenerative medicines based on mitochondrial Complex I modulators (MCMs), a novel class of small molecule drugs that activate the body's natural repair mechanisms to regenerate damaged tissue. Its lead clinical candidate, leramistat, is in Phase 2 trials for sarcopenia caused by rheumatoid arthritis, with a broader pipeline targeting chronic age-related diseases.

Is Istesso a public or private company?

Istesso is a private company. It is classified as venture growth investor backed and is currently operating.

When was Istesso founded?

Istesso was founded in 2017. It employs 1 to 10 people.

Where is Istesso based?

Istesso is headquartered in London, United Kingdom, in the Europe region.

How does Istesso make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Istesso's main competitors?

Direct peers on record are Stealth BioTherapeutics, Khondrion and Abliva (formerly NeuroVive Pharmaceutical). Emerging players are BioAge Labs, UNITY Biotechnology, CohBar (now shareholders-led), AgeX Therapeutics and GenSight Biologics. Mitobridge (acquired by Astellas) is listed as an others. Reata Pharmaceuticals is listed as a broad incumbent.

Does Istesso have an API?

No public API is recorded for Istesso.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyIstesso advances regenerative approach to muscle lossLondon-based regenerative medicine company Istesso has initiated a Phase 2 clinical trial, IST-03, evaluating its lead candidate leramistat as an oral therapy for sarcopenia associated with rheumatoid arthritis, with enrollment now underway at Newcastle University and Newcastle Hospitals. The trial will assess whether the drug, a mitochondrial complex I modulator designed to activate the body's own repair mechanisms, can improve muscle quality, repair, and physical function in patients experiencing disease-related muscle loss. There are currently no approved medicines specifically targeting sarcopenia, a condition affecting an estimated one in three adults over 60 that increases risks of falls, fractures, hospitalization, and mortality.ProactiveinvestorsIP Group's Istesso starts phase II trial of leramistat in sarcopeniaIP Group PLC's portfolio company Istesso has begun dosing patients in a phase II clinical trial (IST-03) of leramistat for sarcopenia, a condition involving muscle loss caused by rheumatoid arthritis. The randomized, double-blind, placebo-controlled study will assess the drug's effects on muscle quality, repair, and function at trial sites including Newcastle University and Newcastle Hospitals, working with the National Institute for Health and Care Research. IP Group holds an undiluted 56.5% stake in Istesso, and CEO Greg Smith described the trial as an important inflection point that could validate the company's regenerative medicine approach if successful.Investing.comIstesso begins phase 2 trial of leramistat for muscle loss By Investing.comIstesso has begun dosing patients in a Phase 2 clinical trial of leramistat for sarcopenia caused by rheumatoid arthritis, marking a significant milestone as no specific pharmacological therapies currently exist for this condition. The randomized, double-blind, placebo-controlled study, designated IST-03, will evaluate the effects of leramistat on muscle quality, repair, and function. Enrollment is underway at Newcastle University and Newcastle Hospitals in conjunction with the National Institute for Health and Care Research.YahooIP Group's Istesso starts phase II trial of leramistat in sarcopeniaIstesso began dosing patients in a phase II trial of leramistat for sarcopenia, a muscle-loss condition linked to rheumatoid arthritis. The randomized, double-blind, placebo-controlled study will assess effects on muscle quality, repair, and function. Preclinical data and earlier rheumatoid arthritis results support the drug's potential.Longevity.TechnologyIstesso takes new route on leramistat for muscle repairLondon-based biotech Istesso has announced new strategic directions for its mitochondrial modulation platform, with post-hoc analyses from a Phase 2b rheumatoid arthritis trial revealing that its lead candidate leramistat demonstrated muscle-protective effects, including reduced levels of the neuromuscular junction breakdown biomarker CAF-22. The company now plans to advance leramistat specifically for musculoskeletal repair indications including age-related sarcopenia, osteoporosis, and osteosarcopenia, and has nominated MBS2687 as its next development candidate in the MCM pipeline. Istesso has already secured FDA Fast Track and Orphan Drug Designation for leramistat in idiopathic pulmonary fibrosis.dlvr.itFDA grants fast-track designation for Istesso’s IPF candidateThe FDA granted fast-track and orphan drug designation for Istesso's MBS2320, an investigational metabolic reprogramming agent for idiopathic pulmonary fibrosis. The designation provides development incentives, including seven years of US market exclusivity. A clinical study in IPF patients will commence in 2023.